ImmunoCellular Therapeutics, Ltd. — Operating Income by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/44218d64-5133-4078-902c-ded3f50d6c56/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2017 | $-21.2M | 2017-01-01 – 2017-12-31 | evidence 0000822411-18-000004 |
| FY 2016 | $-24.1M | 2016-01-01 – 2016-12-31 | evidence 0001628280-17-002439 |
| FY 2015 | $-15.5M | 2015-01-01 – 2015-12-31 | evidence 0001628280-16-013931 |
| FY 2014 | $-9.9M | 2014-01-01 – 2014-12-31 | evidence 0001564590-15-001446 |
| FY 2013 | $-51.6M | 2004-03-01 – 2014-03-31 | evidence 0001564590-14-002006 |
| FY 2012 | $-41.7M | 2004-02-25 – 2013-03-31 | evidence 0000950123-13-003511 |
| FY 2011 | $-30.6M | 2004-02-25 – 2012-03-31 | evidence 0001193125-12-228131 |
| FY 2010 | $-5.1M | 2010-01-01 – 2010-12-31 | evidence 0001193125-12-125451 |
| FY 2009 | $-2.6M | 2009-01-01 – 2009-12-31 | evidence 0001193125-12-125451 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
ImmunoCellular Therapeutics, Ltd. — all facts · Revenue · Net Income